Articles tagged "Heart transplant patients"

2018 American Transplant Congress
A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients
G. Burckart,¹ M. Cavaillé-Coll,² A. Duong,³ L. Hothem,⁴ R. Albrecht.²
¹Office of Clinical Pharmacology, Office of Translational Science, CDER, US Food and Drug Administration, Silver Spring, MD; ²Division of Transplant and Opthalmology Products, Office of New Drugs, CDER, US Food and Drug Administration, Silver Spring, MD; ³Tauro University, New York, NY; ⁴University of North Carolina, Chapel Hill, NC.
The development of drugs for organ transplantation spanned the time before and after pediatric regulatory requirements under the Best Pharmaceuticals for Children Act (BPCA) and…
2018 American Transplant Congress
Heart and Lung Transplantation Outcomes in HIV-Positive Recipients
C. Koval,¹ M. Malinis,² N. Mueller,³ J. Krisl,⁴ M. Hannan,⁵ P. Grossi,⁶ S. Huprikar.⁷
¹Infectious Diseases, Cleveland Clinic, Cleveland, OH; ²Infectious Diseases, Yale University, New Haven, CT; ³Infectious Diseases, University Hospital Zurich, Zurich, Switzerland; ⁴Pharmacy, Houston Methodist Hospital, Houston, TX; ⁵Infectious Diseases, Mater Hospital, Dublin, Ireland; ⁶Infectious Diseases, University Insubria, Varese, Italy; ⁷Infectious Diseases, Mount Sinai Hospital, New York, NY.
Purpose: Data for HIV+ patients receiving heart (HT) or lung transplantation (LT) are limited but appear to demonstrate acceptable outcomes. We aimed to add to…
2018 American Transplant Congress
Pre-Transplant Memory Patients Even without Detected Antibody Are at Rejection Risk in the First-Year after Heart Transplantation
J. Patel, M. Kittleson, E. Kransdorf, R. Levine, S. Dimbil, D. Geft, D. Chang, L. Czer, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles.
Purpose: Patients (pts) with prior transplants, blood transfusions, and pregnancies awaiting heart transplantation (HTx) have potential to develop circulating anti-HLA antibodies (HLA Abs). Pts at…
2018 American Transplant Congress
The Effect of Pre-Transplant Insomnia and Post-Transplant Insomnia on Survival among Solid Organ Recipients
K-.F. Lee,² Y. Tsai,¹ C. Lin,¹ C-.B. Hsieh,^3,5 S. Wu,⁴ T. Chen,⁵ Y-.C. Lin,¹ W-.H. Lee,^6,7 F. Lin,⁸ C. Tsai.^1,9,10
¹Cardiovascular Surgery, Tri-Service General Hospital, Taipei, Taiwan; ²Biobank Management Center, Tri-Service General Hospital, Taipei, Taiwan; ³General Surgery, Hualien Armed Forces General Hospital, Hualien County, Taiwan; ⁴Urology, Tri-Service General Hospital, Taipei, Taiwan; ⁵General Surgery, Tri-Service General Hospital, Taipei, Taiwan; ⁶Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; ⁷Pathology, Taipei Medical University-Shuang Ho Hospital, New Taipei, Taiwan; ⁸Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; ⁹Cardiovascular Surgery, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan; ¹⁰Graduate Institute of Pharmacology, National Defense Medical Center, Taipei, Taiwan.
BackgroundBecause studies about insomnia among organ recipients were scarce, we used National Health Insurance Research Database (NHIRD) between 2001 and 2012 to understand how pre-transplant…
2017 American Transplant Congress
Optimal Induction Therapy for Kidney Transplantation in Previous Heart Transplant Recipients: Analysis of OPTN/UNOS Registry.
M. Sampaio, S. Hussain, B. Chopra, K. Sureshkumar.
Nephrology, Internal Medicine, Allegheny General Hospital, Pittsburgh, PA
It is unclear as to which induction agent is optimal for kidney transplant (KT) in prior heart transplant (HT) recipients who are already immunocompromised from…
2017 American Transplant Congress
Identification of Promising Targets for Tolerance Induction Following Heart Transplantation.
K. Klaeske, M.-T. Dieterlen, J. Fischer, J. Hahn, K. Jawad, J. Garbade, F. Mohr, S. Lehmann.
Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany
Introduction: Tolerance-inducing cell subsets which can support the organ acceptance following heart transplantation (HTx) can be found among dendritic cells (DCs) and regulatory T cells…
2017 American Transplant Congress
Photopheresis for Recalcitrant Rejection After Heart Transplantation: Worthwhile?
J. Patel, M. Kittleson, X. Zhang, E. Klapper, T. Aintablian, K. Murayama, L. Czer, D. Geft, D. Chang, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles
Background: Rejection is leading cause of mortality after heart transplantation (HTx). While the rates of rejection have declined over the past few decades from improvement…
2017 American Transplant Congress
Refinement of an Old Faithful: A Standardized Flow Cytometry Approach to Measure Donor-Recipient Alloreactivity (a Pilot Study).
A. Halpin,¹ M. Sosniuk,¹ S. Urschel,¹ P. Campbell,² I. Larsen,¹ L. West.¹
¹Pediatrics, Alberta Transplant Institute, Canadian National Transplant Reseach Program, University of Alberta, Edmonton, Canada; ²Lab Medicine and Pathology, University of Alberta, Edmonton, Canada
Purpose: Donor-specific antibody (DSA) and antibody (Ab)-mediated rejection are challenges in long-term outcomes and limit re-transplantation. Sensitizing events such as homografts in surgical procedures, assist…
2017 American Transplant Congress
Improved Creatinine Immediately Post-LVAD Predicts Lower AKI Risk After Heart Transplant.
A. Nanavati,¹ Y. He,³ N. Moazami,² S. Demirjian,¹ B. Stephany.¹
¹Nephrology, Cleveland Clinic, Cleveland, OH; ²Heart and Vascular Institute,Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; ³University of Rochester, Rochester, NY
Background-Left ventricular assist device(LVAD) placement often improves renal function in patients with advanced heart failure. In those bridged to transplant with LVAD support it is…
2017 American Transplant Congress
Evaluation of the Conversion from Brand Name to Generic Immunosuppression in Hospitalized Organ Transplant Recipients.
L. DeZotell,¹ K. Blunck,¹ J. Guy,¹ M. Woods,¹ M. Reffett,² J. Terrell,² A. Palermo,² K. Gosch,³ L. Cummings.⁴
¹Department of Pharmacy, Saint Luke's Hospital, Kansas City, MO; ²Transplant Quality Department, Saint Luke's Hospital, Kansas City, MO; ³Cardiovascular Outcomes Research, Saint Luke's Hospital, Kansas City, MO; ⁴Abdominal Transplant and HPB Surgery, Saint Luke's Transplant Specialists, Kansas City, MO
Purpose: Safe and effective immunosuppressant medications are critical to accomplish good graft and patient survival rates. The availability of “AB-rated” generic immunosuppression affords the opportunity…